The use of Xestospongin C, a reversible IP3R antagonist, was evaluated with APP/PS1 AD mice, showing an improvement in cognitive behavior, as evaluated by the Y maze and the Morris water maze, a reduction in the number of Aβ plaques, and a reduction in the levels of ER-stress proteins [344]. Here, APP is linked to Alzheimer disease.